BioCardia, Inc. (NASDAQ:BCDA) Director Simon H. Stertzer Acquires 22,753 Shares of Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon H. Stertzer purchased 22,753 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was purchased at an average cost of $2.30 per share, for a total transaction of $52,331.90. Following the acquisition, the director now owns 40,602 shares of the company’s stock, valued at approximately $93,384.60. This trade represents a 127.47 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

BioCardia Trading Up 0.8 %

Shares of NASDAQ:BCDA opened at $2.54 on Thursday. The stock’s 50-day moving average price is $2.34 and its 200-day moving average price is $2.44. The stock has a market capitalization of $11.64 million, a P/E ratio of -0.61 and a beta of 1.28. BioCardia, Inc. has a 12-month low of $1.63 and a 12-month high of $6.90.

Wall Street Analysts Forecast Growth

BCDA has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of BioCardia in a research note on Wednesday, December 18th. Alliance Global Partners raised BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th.

Institutional Trading of BioCardia

A hedge fund recently bought a new stake in BioCardia stock. CM Management LLC bought a new position in shares of BioCardia, Inc. (NASDAQ:BCDA) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $54,000. CM Management LLC owned 0.55% of BioCardia at the end of the most recent quarter. 20.57% of the stock is currently owned by institutional investors and hedge funds.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.